Last reviewed · How we verify
Intravitreal Antibiotics
Intravitreal antibiotics are antimicrobial agents injected directly into the vitreous cavity of the eye to treat or prevent bacterial infections within the eye.
Intravitreal antibiotics are antimicrobial agents injected directly into the vitreous cavity of the eye to treat or prevent bacterial infections within the eye. Used for Bacterial endophthalmitis, Intraocular bacterial infection prophylaxis.
At a glance
| Generic name | Intravitreal Antibiotics |
|---|---|
| Sponsor | National Eye Institute (NEI) |
| Drug class | Antibiotic |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
By delivering antibiotics directly to the vitreous humor, this approach achieves high local drug concentrations at the site of infection while minimizing systemic exposure and side effects. This route is particularly useful for treating endophthalmitis and other intraocular bacterial infections that are difficult to reach with systemic antibiotics due to the blood-retinal barrier. The direct intravitreal administration allows for rapid antimicrobial action against bacteria colonizing the posterior segment of the eye.
Approved indications
- Bacterial endophthalmitis
- Intraocular bacterial infection prophylaxis
Common side effects
- Retinal toxicity
- Cataract formation
- Vitreous hemorrhage
- Endophthalmitis (if infection not controlled)
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine (PHASE4)
- A Feasibility Randomised Controlled Trial of Early Vitrectomy for Post-operative Exogenous Endophthalmitis (NA)
- Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy
- Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients (EARLY_PHASE1)
- Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis (NA)
- Sirolimus for Retinal Astrocytic Hamartoma (NA)
- Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |